Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(20%)
Results Posted
0%(0 trials)

Phase Distribution

No phase data available

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(2)

Detailed Status

Not yet recruiting2
Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%

Trials by Status

not_yet_recruiting240%
completed240%
recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
not_yet_recruiting

EVOLUTION OF D-DIMER AS A MARKER OF BLEEDING RISK ON ECMO

NCT07039513
not_yet_recruiting

EVALUATION OF NEUTROPHIL FLUORESCENCE IN PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION ASSOCIATED WITH SEPTIC SHOCK

NCT07039487
recruiting

Early Retinal Neurodegeneration As Risk Factor, Biomarker and Pharmacological Target of Diabetic Retinopathy

NCT06582472
completed

Open Study of the Duration of Immunity After Vaccination With GamEvac

NCT02911428
completed

Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi

NCT02911415

Clinical Trials (5)

Showing 5 of 5 trials
NCT07039513

EVOLUTION OF D-DIMER AS A MARKER OF BLEEDING RISK ON ECMO

Not Yet Recruiting
NCT07039487

EVALUATION OF NEUTROPHIL FLUORESCENCE IN PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION ASSOCIATED WITH SEPTIC SHOCK

Not Yet Recruiting
NCT06582472

Early Retinal Neurodegeneration As Risk Factor, Biomarker and Pharmacological Target of Diabetic Retinopathy

Recruiting
NCT02911428

Open Study of the Duration of Immunity After Vaccination With GamEvac

Completed
NCT02911415

Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi

Completed

All 5 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
5